Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific monoclonal antibodies in multiple myeloma. When approved, the optimal use for these therapies would be in triple-refractory myeloma patients, but these strategies will move into earlier lines of treatment in the future. Currently, ongoing clinical trials are evaluating the role of bispecifics and CAR T-cells following one/three prior lines of therapy. While other trials are evaluating the safety and efficacy of CAR T-cells in the front-line setting in patients with high-risk myeloma. Dr Mateos highlights different strategies, currently being investigated in preliminary clinical trials, to improve the efficacy of BCMA CAR T-cells. In the bispecific antibody field, new targets beyond BCMA are being investigated, including GPRC5D-directed bispecifics, as well as novel combinations of immune and targeted therapies. This interview took place during the 3rd European CAR T-cell Meeting.